How we made the decision

Exceptionally, significant new evidence may mean an update of a guideline is agreed before the next scheduled check of the need for an update. The evidence might be a single piece of evidence, an accumulation of evidence or other published NICE guidance.

For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.

Evidence

This exceptional review provides an overview of 1 study published since the end of the search period for the surveillance review (November 2016). The results of this study were considered in detail to determine if there is an impact on guideline recommendations.

No additional evidence published since the surveillance review of the guideline in April 2017 was considered.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline.

Views of stakeholders

Because this was an exceptional surveillance review we did not consult on the decision.

NICE Surveillance programme project team

Kay Nolan
Associate Director

Janusz Jankowski
Consultant Clinical Adviser

Martin Allaby
Consultant Clinical Adviser

Emma McFarlane
Technical Adviser

Andrea Juliana Sanabria Uribe
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2445-5


This page was last updated: